PSA Data: Cost-Effectiveness Analysis of a Respiratory Diagnostic Test

Raymond Oppong's dataset contains results from a model-based cost-utility analysis of the Biofire Film Array Respiratory Panel RP 2.1+ test for patients with chronic obstructive pulmonary disease (COPD). The analysis, conducted from a healthcare perspective over a 40-year horizon, evaluates the test's cost-effectiveness and potential savings related to antimicrobial resistance (AMR). The dataset, last updated on 2026-04 27, is a 627.2 KB XLSX file.

Use Cases

• Modeling healthcare cost savings based on the reported £2762.40 cost difference and 0.03 QALY gain.
• Assessing the probability of cost-effectiveness based on the reported 70% chance.
• Estimating the potential annual financial impact of a diagnostic test based on the reported savings range of £118 million to £18.6 billion.
• Analyzing approaches to incorporate antimicrobial resistance costs into economic evaluations, as described in the methods.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions.
• The analysis adopts a long-term 40-year healthcare perspective.
• The dataset explicitly attempts to account for antimicrobial resistance costs using two distinct approaches.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description is focused on study results; the specific data columns and structure are not detailed.

Provenance

Source

Raymond Oppong

Collection Method

Model-based cost-utility analysis informed by literature review and expert opinion.

Time Range

Analysis conducted over a 40-year model horizon.

Freshness

Last updated 2026-04-27 17:26:41; freshness should be verified.

Geography

null